Europe or the US? The IPO Data Challenges a Long-Held Assumption

For ambitious European technology companies, there has long been a familiar assumption when the conversation turns to an IPO: the US is where you go to access deeper capital markets, stronger valuations and greater liquidity.
But does the data actually support that assumption?
A new analysis by Euronext, examining European IPOs and listed companies using data through June 2026, suggests the answer is far less straightforward. For many European companies considering their path to the public markets, the numbers make a compelling case for looking closer to home.
Euronext analysed European companies going public since 2021, alongside the wider population of European companies listed in the US and on Euronext. Its findings challenge several of the most persistent perceptions around European versus US listings.
You can access the FULL REPORT HERE.
The European IPO “exodus” is much smaller than the headlines suggest
First, European companies are overwhelmingly continuing to list in Europe.
Since 2021, approximately 95% of European IPOs have taken place on European exchanges. Fewer than 5% chose the US, representing just 45 European companies through June 2026. And that relatively small group was highly concentrated: 47% were healthcare companies, primarily biotech and medtech businesses whose key commercial market is the US. Nearly two-thirds (62%) came from the UK, Germany and Switzerland.
So the idea of European growth companies broadly migrating towards US public markets deserves a closer look.
More importantly, where companies list is only part of the story. What happens after the IPO matters considerably more.
+3% versus -28%: the aftermarket tells a different story
This is perhaps the most striking finding in Euronext’s analysis.
Comparing average one-year post-listing share-price performance for IPOs in its study, Euronext found a 3% gain for companies listing on its markets. European companies listing on Nasdaq recorded -36%, while those listing on the NYSE recorded -8%.
Across European companies listing in the US, average one-year performance was -28%, compared with +3% on Euronext. The analysis also found that 71% of European IPOs in the US were trading, or had been delisted, below their offer price, as of June 2026.
That matters because the IPO itself is only the beginning.
For founders, management teams and existing investors, the real question is not simply “Where can we list?” It is:
Where can the company build a sustainable life as a public company?
What about the famous US valuation premium?
One of the strongest arguments for crossing the Atlantic is valuation. Here again, the picture is more nuanced than conventional wisdom suggests.
According to Euronext’s analysis, average forward valuation multiples are broadly comparable across the two markets. Euronext issuers trade at 9.6x forward EV/EBITDA, versus 9.7x for European issuers listed in the US, while forward P/E multiples are 15.3x and 14.9x, respectively.
More importantly, the analysis finds that the US does not offer a structural valuation premium for most European issuers. Some 80% of European companies listed in the US have a market capitalisation below €10 billion: precisely the range where Euronext issuers trade at a premium. Only a subset of European blue chips above €10 billion command higher valuations in the US than comparable Euronext-listed companies.
In other words, a US listing can make strategic sense for particular companies. But a valuation premium should not simply be assumed because the ticker is trading in New York.
And what about liquidity?
Liquidity is another frequently cited reason for choosing the US. Yet Euronext’s analysis finds that, for European companies, liquidity measured by free-float velocity is broadly comparable across the two markets.
For companies valued between €10 billion and €30 billion, average free-float velocity was identical at 2.7x. Among companies above €30 billion, Euronext issuers recorded higher velocity, while US-listed European companies had the advantage in the €1–10 billion segment.
The implication is clear: greater US market depth does not automatically translate into better liquidity for every European issuer. Company size, investor interest and market visibility matter.
Listing in Europe does not mean giving up access to global capital
Perhaps one of the biggest misconceptions is that choosing Europe means choosing a predominantly European investor pool.
Figures from the Euronext analysis tell a different story.
More than 4,500 institutional investors are active across Euronext markets, representing approximately €3.0 trillion invested. Importantly, that investor base is international: US, UK and continental European investors all participate in the market. US investors alone account for 32% of institutional ownership of Euronext issuers.
Euronext itself represents more than 1,800 listed companies and €7.4 trillion in aggregate market capitalisation, across eight listing venues integrated into a single liquidity pool. It accounts for approximately 26% of European cash-equity trading, with more than €12 billion in average daily equity volume over the last twelve months.
Crucially, a European listing can provide access to US institutional capital without sacrificing proximity to European and UK investors. Euronext’s analysis shows that European and UK investors account for 63% of institutional ownership of Euronext issuers, compared with just 14% for European companies listed in the US.
So the choice is not simply between “European capital” and “global capital”. European markets themselves provide access to international investors.
Visibility matters: research coverage and index inclusion
Beyond valuations and investor access, two factors can significantly influence a company’s long-term experience as a public issuer: analyst coverage and eligibility for major stock-market indices.
Euronext’s analysis finds that equity research coverage is close to US levels across company-size categories. Companies valued between €10 billion and €30 billion, for example, have an average of 14 covering analysts on Euronext, compared with 15 for European companies listed in the US.
Index inclusion is another consideration. Many European companies listed in the US do not meet the eligibility criteria for flagship US indices, while they may be eligible for leading European indices.
For a newly listed growth company, visibility, research coverage and the potential to attract long-term institutional investors should be part of the listing decision from the outset.
Then comes a less glamorous question: how much does it cost?
For scale-ups preparing for an IPO, the economics of the transaction deserve just as much scrutiny as valuation.
Euronext’s analysis estimates that for an illustrative €1 billion company raising €100 million on Euronext, total IPO costs would be approximately 4.5–6.0% of the amount raised. For a comparable $1 billion company raising $100 million on Nasdaq or NYSE, estimated costs rise to 10.5–12.5%. These are illustrative estimates in each market’s local currency, with actual costs depending on the company and transaction.
The biggest differences come from underwriting, legal, documentation, auditing and associated compliance costs. For a growth company, that is extra capital that could otherwise remain available to fund expansion, R&D, acquisitions or internationalisation.
The obligations also continue after listing.
Companies considering their options should take in account greater litigation exposure, D&O insurance costs and regulatory complexity if they are operating under the US framework.
The IPO decision should start earlier than the IPO
None of this means that every European company should list in Europe.
There are businesses for which the US can be the logical market — because of their customer base, sector, investor universe, geographic footprint or long-term strategy.
That is precisely why the more useful question is “Which market is better for this particular company?”
Management location. Customer base. Peer group. Sector expertise. Investor familiarity. Research coverage. Liquidity. Valuation. Regulation. Cost. Index eligibility. Long-term shareholder composition. All of these should be part of the equation.
And that conversation should begin years before an IPO, not months before the opening bell.
For Europe’s most promising scale-ups, preparing early does not mean committing to go public. It means understanding the option, building the right governance and financial infrastructure, developing relationships with public-market investors and ensuring that when the time comes, management can make the decision based on evidence rather than perception.
That is also the thinking behind Euronext’s IPOready programme, a six-month pre-IPO programme designed to help companies prepare for the demands of the public markets well before a potential listing. Through expert guidance, practical insights and access to an extensive network of advisors and peers, the programme helps management teams build the knowledge and readiness needed to evaluate their options and pursue an IPO when the time is right.
Learn more about Euronext IPOready>>>
Because when it comes to European companies and the public markets, the grass on the other side of the Atlantic may not always be greener.
___
To stay connected on further insights and opportunities, sign up for our newsletter below.
Newsletter
Stay up to date with market insights, trailblazing investment cases, and leadership profiles by subscribing to our newsletter.